{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:40:01Z","timestamp":1790170801378,"version":"4.1.0"},"reference-count":19,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Radioimmunotherapy (RIT) is effective in treating relapsed\/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin\u00ae) would result in durable remissions by eliminating minimal residual disease after cytoreduction. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Patients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4\u20136 weeks later if there was no disease progression and bone marrow biopsy showed &amp;#x3c; 25% involvement. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Twenty-eight patients were treated, with a median age of 61 years, median of 3 prior therapies, 49% high-risk disease (Follicular Lymphoma International Prognostic Index, FLIPI), and 39% progressive disease. Three patients did not receive Zevalin due to residual bone marrow involvement. The main toxicities were cytopenias, with 11% febrile neutropenia. The overall response rate (ORR) was 72%, with 45% achieving complete response. With a median follow-up of 73 months, 1-year progression-free survival (PFS) was 38%, and median PFS was 10 months, but median overall survival (OS) was not reached. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; The study did not reach its primary endpoint of a 1-year PFS of 67.3%. Reasons for this could include low accrual, high-risk disease, and inadequate debulking provided by 2 cycles of ESHAP. However, this protocol was associated with tolerable toxicity, high ORR, and high OS. Further studies would optimize debulking and focus on high-risk FL patients.<\/jats:p>","DOI":"10.1159\/000486788","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T22:01:38Z","timestamp":1519336898000},"page":"274-280","source":"Crossref","is-referenced-by-count":17,"title":["Yttrium-90-Ibritumomab Tiuxetan (Zevalin\u00ae) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study"],"prefix":"10.1159","volume":"94","author":[{"given":"Soham\u00a0D.","family":"Puvvada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9\u00a0M.","family":"Guill\u00e9n-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Incl\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8211-4612","authenticated-orcid":false,"given":"Xavier\u00a0I.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daruka","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan\u00a0H.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel\u00a0O.","family":"Persky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70471-8"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0711-0"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1016929"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132142"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13954"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0012-3"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22617"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/486788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/486788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:37:34Z","timestamp":1745426254000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000486788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,24]]},"published-print":{"date-parts":[[2018,5,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000486788","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}